These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 19519393)

  • 41. A novel dual-target steroid sulfatase inhibitor and antiestrogen: SR 16157, a promising agent for the therapy of breast cancer.
    Rasmussen LM; Zaveri NT; Stenvang J; Peters RH; Lykkesfeldt AE
    Breast Cancer Res Treat; 2007 Dec; 106(2):191-203. PubMed ID: 17268816
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Characterization of new estrogen receptor destabilizing compounds: effects on estrogen-sensitive and tamoxifen-resistant breast cancer.
    Hoffmann J; Bohlmann R; Heinrich N; Hofmeister H; Kroll J; Künzer H; Lichtner RB; Nishino Y; Parczyk K; Sauer G; Gieschen H; Ulbrich HF; Schneider MR
    J Natl Cancer Inst; 2004 Feb; 96(3):210-8. PubMed ID: 14759988
    [TBL] [Abstract][Full Text] [Related]  

  • 43. COMP-structure-based design and development of estrogen receptor modulators.
    Rotella D
    IDrugs; 2006 Nov; 9(11):748-50. PubMed ID: 17096289
    [No Abstract]   [Full Text] [Related]  

  • 44. Elucidation of the molecular mechanism of action of selective estrogen receptor modulators.
    McDonnell DP; Wijayaratne A; Chang CY; Norris JD
    Am J Cardiol; 2002 Jul; 90(1A):35F-43F. PubMed ID: 12106639
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Structure-based approach for the discovery of novel selective estrogen receptor modulators.
    Rosano C; Stec-Martyna E; Lappano R; Maggiolini M
    Curr Med Chem; 2011; 18(8):1188-94. PubMed ID: 21291367
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Design and synthesis of norendoxifen analogues with dual aromatase inhibitory and estrogen receptor modulatory activities.
    Lv W; Liu J; Skaar TC; Flockhart DA; Cushman M
    J Med Chem; 2015 Mar; 58(6):2623-48. PubMed ID: 25751283
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Estrogen signaling: An emanating therapeutic target for breast cancer treatment.
    Saha T; Makar S; Swetha R; Gutti G; Singh SK
    Eur J Med Chem; 2019 Sep; 177():116-143. PubMed ID: 31129450
    [TBL] [Abstract][Full Text] [Related]  

  • 48. "Cherchez La Femme": Modulation of Estrogen Receptor Function With Selective Modulators: Clinical Implications in the Field of Urology.
    Helo S; Wynia B; McCullough A
    Sex Med Rev; 2017 Jul; 5(3):365-386. PubMed ID: 28372959
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Estrogen receptor agonists/antagonists in breast cancer therapy: A critical review.
    Jameera Begam A; Jubie S; Nanjan MJ
    Bioorg Chem; 2017 Apr; 71():257-274. PubMed ID: 28274582
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Oestrogen receptors and selective oestrogen receptor modulators: molecular and cellular pharmacology.
    Nilsson S; Koehler KF
    Basic Clin Pharmacol Toxicol; 2005 Jan; 96(1):15-25. PubMed ID: 15667591
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Structure-function relationships in estrogen receptors and the characterization of novel selective estrogen receptor modulators with unique pharmacological profiles.
    Katzenellenbogen BS; Sun J; Harrington WR; Kraichely DM; Ganessunker D; Katzenellenbogen JA
    Ann N Y Acad Sci; 2001 Dec; 949():6-15. PubMed ID: 11795381
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Combinatorial chemistry in steroid receptor drug discovery.
    Flygare JA; Sutherlin DP; Brown SD
    Methods Mol Biol; 2001; 176():353-8. PubMed ID: 11554335
    [No Abstract]   [Full Text] [Related]  

  • 53. Structure-activity relationships for a family of benzothiophene selective estrogen receptor modulators including raloxifene and arzoxifene.
    Overk CR; Peng KW; Asghodom RT; Kastrati I; Lantvit DD; Qin Z; Frasor J; Bolton JL; Thatcher GR
    ChemMedChem; 2007 Oct; 2(10):1520-6. PubMed ID: 17654759
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Selective estrogen receptor modulators for postmenopausal osteoporosis: current state of development.
    Gennari L; Merlotti D; Valleggi F; Martini G; Nuti R
    Drugs Aging; 2007; 24(5):361-79. PubMed ID: 17503894
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evolution of the tissue selective estrogen complex (TSEC).
    Komm BS; Mirkin S
    J Cell Physiol; 2013 Jul; 228(7):1423-7. PubMed ID: 23359290
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tetrahydroquinoline-based selective estrogen receptor modulators (SERMs).
    Wallace OB; Lauwers KS; Jones SA; Dodge JA
    Bioorg Med Chem Lett; 2003 Jun; 13(11):1907-10. PubMed ID: 12749895
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficient synthesis of a multi-substituted diphenylmethane skeleton as a steroid mimetic.
    Misawa T; Tanaka K; Demizu Y; Kurihara M
    Bioorg Med Chem Lett; 2017 Jun; 27(11):2590-2593. PubMed ID: 28400239
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Estrogen receptors: therapies targeted to receptor subtypes.
    Nilsson S; Gustafsson JÅ
    Clin Pharmacol Ther; 2011 Jan; 89(1):44-55. PubMed ID: 21124311
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Impact of the nuclear receptor coactivator AIB1 isoform AIB1-Delta3 on estrogenic ligands with different intrinsic activity.
    Reiter R; Oh AS; Wellstein A; Riegel AT
    Oncogene; 2004 Jan; 23(2):403-9. PubMed ID: 14691461
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Are estrogen receptor content in breast cancer and effects of tamoxifen on sex hormone-binding globulin markers for individual estrogen sensitivity?
    Löfgren L; von Schoultz E; Fernstad R; von Schoultz B; Carlström K
    J Steroid Biochem Mol Biol; 2006 Apr; 99(1):76-9. PubMed ID: 16621526
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.